164 results on '"Valent A"'
Search Results
2. Clonal medicine targeting DNA damage response eradicates leukemia
3. The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification
4. CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS
5. Engraftment in NSGSCF mice correlates with the WHO category and prognosis in systemic mastocytosis
6. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
7. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
8. Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia
9. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
10. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry
11. Identification of a leukemia-initiating stem cell in human mast cell leukemia
12. Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia
13. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex
14. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
15. Engraftment in NSGSCF mice correlates with the WHO category and prognosis in systemic mastocytosis
16. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer
17. Pharmacologic inhibition of STAT5 in acute myeloid leukemia
18. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
19. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
20. Proposed diagnostic criteria and classification of basophilic leukemias and related disorders
21. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis
22. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis
23. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
24. NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells
25. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth
26. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis
27. Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia
28. O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies
29. NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors
30. Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia
31. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q
32. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
33. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis
34. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event
35. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
36. Refined diagnostic criteria for bone marrow mastocytosis : a proposal of the European competence network on mastocytosis
37. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS
38. Engraftment in NSGSCFmice correlates with the WHO category and prognosis in systemic mastocytosis
39. Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia
40. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
41. Monosomal karyotype in MDS: explaining the poor prognosis?
42. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
43. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group
44. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
45. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
46. A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells
47. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
48. Pharmacologic inhibition of STAT5 in acute myeloid leukemia
49. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)
50. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.